All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-04-12T12:49:00.000Z

AACR 2017 | Poster 4589/4 – Preclinical investigation of the novel SGN-CD70A antibody drug conjugate in T-Cell Lymphomas

Apr 12, 2017
Share:

Bookmark this article

At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “Immunoconjugates and Antibodies” took place.

One of the posters on display (4589 / 4) was titled “Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas” by Chen-Yen Yang from University of California San Francisco, San Francisco, CA, and colleagues.

SGN-CD70A is a novel antibody drug conjugate; an anti-CD70 monoclonal antibody joined to a pyrrolobenzodiazepine (PBD) dimer (synthetic DNA cross-linking molecule). This group aimed to evaluate the anti-tumor activity of SGN-CD70A in T-Cell Lymphomas (TCLs).

Key Highlights:

  • CD70 expression was reported in all subtypes of TCL and all Cutaneous T-Cell Lymphoma (CTCL) cell lines
  • CD70 was not expressed in peripheral blood mononuclear cells from healthy subjects
  • SGN-CD70A had no significant activity in CD70-negative T-ALL lines, however potently inhibited cell growth in CD70-positive CTCL lines
  • SGN-CD70A was more efficient at inducing apoptosis and cell death in CTCL cell lines compared with media and h00d-1910 treated controls
  • In a dose-dependent manner, SGN-CD70A inhibited cell proliferation and induced higher caspase 3/7 activity in CD70-positive patient-derived TCL primary cells, while h00d-1910 treated in parallel had no significant effects

In conclusion, this poster stated that CD70 is not expressed by healthy donor cells, but is expressed by nodal and cutaneous TCLs. The antibody drug conjugate SGN-CD70A demonstrated anti-tumor activity in CTCL cell lines as well as in patient derived TCL primary cells. These data indicate that SGN-CD70A is a promising therapeutic option for TCLs.

  1. Yang C.Y. et al. Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas [Poster]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [4589 / 4].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox